Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Anaes TopicsApplied cardiovascular & respiratory physiology

Anaes · Applied cardiovascular & respiratory physiology

ADME and routes of drug administration

Also known as ADME · Absorption distribution metabolism excretion · Routes of administration · Bioavailability · First-pass metabolism · pH partition hypothesis

ADME — absorption, distribution, metabolism and excretion — is the pharmacokinetic backbone that determines how much of a drug reaches its site of action, how quickly, and how long it stays. The route of administration sets the starting point of that journey and is one of the most important practical decisions in anaesthetic practice. The framework rests on six exam-critical ideas. First, the four ADME processes are sequential and interactive: a drug must be absorbed into the systemic circulation (unless given intravenously), distributed to its site of action, metabolised (chiefly by the liver) to a more water-soluble form, and excreted (chiefly by the kidney). Second, bioavailability is the fraction of the administered dose that reaches the systemic circulation unchanged; it is 1.0 (100 percent) for an intravenous dose and is reduced for oral drugs by incomplete absorption and by first-pass (presystemic) metabolism in the gut wall, the portal blood and the liver, which is why an oral dose is almost always larger than the equivalent intravenous dose. Third, the common routes differ sharply in onset and bioavailability: intravenous is instantaneous and complete (100 percent bioavailability) but irreversible; intramuscular and subcutaneous are near-complete and take minutes; inhalational is rapid (the lung is a superb absorption surface with a huge area and thin barrier) and titratable; oral is convenient but slow and limited by first-pass metabolism; transdermal is slow and sustained; sublingual and intranasal bypass first-pass metabolism. Fourth, absorption across a biological membrane depends on surface area, blood flow, and most fundamentally on the drug's ionisation — only the unionised (lipid-soluble) fraction crosses lipid membranes, described by the pH partition hypothesis and the Henderson-Hasselbalch equation. Fifth, drug metabolism occurs in two phases: Phase I (oxidation, reduction, hydrolysis, chiefly by the cytochrome P450 superfamily) which often unmasks or introduces a functional group, and Phase II (conjugation with glucuronide, sulphate, acetate or glutathione) which makes the molecule more water-soluble for excretion; many drugs are administered as inactive prodrugs that require Phase I or II conversion to their active form. Sixth, excretion is mainly renal (glomerular filtration, active tubular secretion, and passive tubular reabsorption that is pH-dependent) and biliary, with enterohepatic recirculation prolonging the action of some drugs. Built on the oral S-ketamine pharmacokinetic study (van Mechelen 2026), the CYP450 metaboliser phenotype study (Oskay 2026), the subcutaneous absorption modelling review (Siemiątkowska 2026), the transdermal patch permeation study (Garg 2026), the mycophenolic-acid enterohepatic-recirculation report (Śmiertka 2026), the intranasal administration review (Jafarbeglou 2026), the intestinal-fluid solubilisation and lipophilicity study (Boyanov 2026), and the renal-impairment pharmacokinetic study (Kojima 2026).

high8 referencesUpdated 26 July 20269 min readVerification in progress

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

ANZCAFRCAABAEDAICFCAIFCA_SA

Red flags

  • Bioavailability is the fraction of the administered dose reaching the systemic circulation UNCHANGED. It is 1.0 for an intravenous dose and is reduced for oral drugs by incomplete absorption AND by first-pass (presystemic) metabolism in the gut wall, portal blood and liver — this is why the oral dose of a drug (e.g. propranolol, morphine, lidocaine) is many times the intravenous dose.
  • Only the UNIONISED, lipid-soluble fraction of a drug crosses a lipid membrane (the pH partition hypothesis). Weak acids are trapped in alkaline urine and weak bases in acidic urine — the basis of ion trapping and of urinary alkalinisation for salicylate poisoning.
  • Metabolism is in TWO phases. Phase I (oxidation/reduction/hydrolysis, chiefly CYP450) often makes the drug more polar but sometimes MORE active (prodrug activation) or more toxic (bioactivation). Phase II (conjugation — glucuronidation, sulphation) almost always makes the drug more water-soluble and inactive for excretion.
  • The LIVER is the main metabolic organ, with extrahepatic contribution from the gut wall (which metabolises drugs such as midazolam and morphine before they ever reach the liver), lung, kidney and plasma.
  • Renal excretion has three mechanisms — glomerular filtration (of the unbound drug), active tubular secretion (of acids and bases by separate transporters, the basis of probenecid competition) and passive pH-dependent reabsorption. Renal failure prolongs the action of renally cleared drugs (e.g. many neuromuscular blockers) and requires dose reduction.
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

ANZCAFRCAABAEDAICFCAIFCA_SA

Red flags

  • Bioavailability is the fraction of the administered dose reaching the systemic circulation UNCHANGED. It is 1.0 for an intravenous dose and is reduced for oral drugs by incomplete absorption AND by first-pass (presystemic) metabolism in the gut wall, portal blood and liver — this is why the oral dose of a drug (e.g. propranolol, morphine, lidocaine) is many times the intravenous dose.
  • Only the UNIONISED, lipid-soluble fraction of a drug crosses a lipid membrane (the pH partition hypothesis). Weak acids are trapped in alkaline urine and weak bases in acidic urine — the basis of ion trapping and of urinary alkalinisation for salicylate poisoning.
  • Metabolism is in TWO phases. Phase I (oxidation/reduction/hydrolysis, chiefly CYP450) often makes the drug more polar but sometimes MORE active (prodrug activation) or more toxic (bioactivation). Phase II (conjugation — glucuronidation, sulphation) almost always makes the drug more water-soluble and inactive for excretion.
  • The LIVER is the main metabolic organ, with extrahepatic contribution from the gut wall (which metabolises drugs such as midazolam and morphine before they ever reach the liver), lung, kidney and plasma.
  • Renal excretion has three mechanisms — glomerular filtration (of the unbound drug), active tubular secretion (of acids and bases by separate transporters, the basis of probenecid competition) and passive pH-dependent reabsorption. Renal failure prolongs the action of renally cleared drugs (e.g. many neuromuscular blockers) and requires dose reduction.
The one-line answer

ADME — absorption, distribution, metabolism, excretion — is the pharmacokinetic backbone that decides how much drug reaches its site of action, how fast, and for how long, and the route of administration sets the starting line. Bioavailability is the fraction reaching the systemic circulation unchanged (1.0 for intravenous, cut down for oral by incomplete absorption and first-pass metabolism). Only the unionised, lipid-soluble fraction crosses a membrane (the pH partition hypothesis). Metabolism runs in two phases — Phase I (CYP450) can inactivate, activate or toxify; Phase II conjugation makes the drug water-soluble and inactive. Renal excretion has three mechanisms, and renal failure demands dose reduction of cleared drugs.[1][2]

Meet the patient

You push propofol into a vein and the patient is asleep in one arm-to-brain circulation; an hour later you give the same patient an oral premedication that barely registers in the plasma. The contrast is the whole topic in one breath: the intravenous bolus bypasses absorption entirely, while the oral tablet is delayed and attenuated by first-pass metabolism. ADME is the framework that predicts onset, peak, duration and dose — and lets you dose safely in organ failure.[1]

Hold the route and the rest follows: the route sets bioavailability, and bioavailability sets the dose. Every absorption barrier, every first-pass loss, every ion-trapping trick is a refinement of that single idea.[1]

Anaesthesia Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Anaesthesia fellowship library.

Sign in to continueSee pricing
References8ShowHide
  1. [1]van Mechelen JC, et al. Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants J Psychopharmacol, 2026.PMID 42345469
  2. [2]Oskay A, et al. CYP450 Metabolizer Phenotypes in a Turkish Emergency Cardiac Patient Cohort: A Descriptive Pharmacogenomic Study Pharmaceuticals (Basel), 2026.PMID 42356431
  3. [3]Siemiątkowska A, et al. Pharmacokinetic modeling and quantitative prediction of subcutaneous absorption of antibody-based therapeutics - An update Adv Drug Deliv Rev, 2026.PMID 42251864
  4. [4]Garg I, et al. Understanding drug diffusion and permeation in transdermal patches: A kinetic perspective Eur J Pharm Biopharm, 2026.PMID 42315040
  5. [5]Śmiertka A, et al. Elevated mycophenolic acid levels after kidney transplantation: avoiding unnecessary dose reduction through team-based TDM interpretation Folia Med Cracov, 2026.PMID 42295072
  6. [6]Jafarbeglou M, et al. A Multispecies Systematic and Critical Review of Intranasal Administration in Veterinary Anaesthesia and Emergency Care: Promising Evidence and Overlooked Challenges Vet Med Sci, 2026.PMID 42313899
  7. [7]Boyanov T, et al. Drug Solubilization in Simulated Intestinal Fluids vs Lipophilicity: Does Charge Matter? Mol Pharm, 2026.PMID 41574874
  8. [8]Kojima T, et al. Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration Eur J Clin Pharmacol, 2026.PMID 42032338

Test yourself

Practise what you just read

  • 8 MCQs
Anaesthesia Pro

$29/ monthor $279 / year

The complete Anaesthesia library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAcid-base: the Stewart approachApplied cardiovascular & respiratory physiologyNextApplied cardiovascular & respiratory physiologyApplied cardiovascular & respiratory physiology